retatrutide type 2 diabetes phase 2 results 2024 2025 💉 may be redefining obesity treatment. New data from TRIUMPH-1 Trial showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic retatrutide phase 2 trial type

More efficient penetration has been shown through directly comparing GSH to a GSH monoethyl ester (GEE), showing that GEE significantly elevated intracellular GSH levels in mesencephalic cultures (Zeevalk et al., 2007)

The tirzepatide enforcement shift The FDA determined that the tirzepatide shortage was resolved, and Eli Lilly demonstrated adequate supply

Tirzepatide has been approved for marketing in China and is indicated for long-term weight management in patients with obesity or overweight

Also read: Science-Based Hydration Strategies for Better Living & Performance You Didnt Know (05/05/25) Longevity community couldnt resist GLP1s Given our newsletters core focus is on longevity itself, we couldnt help but give the perspective of the longevity community on GLP-1s and other WLMs